Evidence map›Paper›PMID 9121481›Full record

ArticleMolecular and cellular biology1997

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.

D Bischof, K Pulford, D Y Mason, S W Morris

Abstract read
In one paragraph

Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed.

  1. Article
  2. Article
  3. ALK+ Anaplastic Large Cell Lymphoma Diagnosed on Paediatric Pericardial Effusion Cytology.Cytopathology : official journal of the British Society for Clinical Cytology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

D BischofDepartment of Experimental Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
K Pulford
D Y Mason
S W Morris

Funding

NPM-ALK AND ALK IN LYMPHOMA AND NORMAL DEVELOPMENTR01CA069129 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MORRIS, STEPHAN W · 1996 to 2006
$2.0M
MOLECULAR ANALYSIS OF T(3;5) IN ACUTE MYELOID LEUKEMIAK08CA001702 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MORRIS, STEPHAN W · 1992 to 1996
–
NCI NIH HHS CA 01702NCI NIH HHS CA 27165NCI NIH HHS CA 69129
6 · The paper itself

Abstract

The NPM-ALK fusion gene, formed by the t(2;5)(p23;q35) translocation in non-Hodgkin's lymphoma, encodes a 75-kDa hybrid protein that contains the amino-terminal 117 amino acid residues of the nucleolar phosphoprotein nucleophosmin (NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase ALK (anaplastic lymphoma kinase). Here, we demonstrate the transforming ability of NPM-ALK and show that oncogenesis by the chimeric protein requires the activation of its kinase function as a result of oligomerization mediated by the NPM segment. Sedimentation gradient experiments revealed that NPM-ALK forms in vivo multimeric complexes of approximately 200 kDa or greater that also contain normal NPM. Cell fractionation studies of the t(2;5) translocation-containing lymphoma cell line SUP-M2 showed NPM-ALK to be localized within both the cytoplasmic and nuclear compartments. Immunostaining performed with both polyclonal and monoclonal anti-ALK antibodies confirmed the dual location of the oncoprotein and also indicated that NPM-ALK is abundant within both the nucleoplasm and the nucleolus. An intact NPM segment is absolutely required for NPM-ALK-mediated oncogenesis, as indicated by our observation that three different NPM-ALK mutant proteins lacking nonoverlapping portions of the NPM segment were each unable to form complexes, lacked kinase activity in vivo, and failed to transform cells. However, NPM could be functionally replaced in the fusion protein with the portion of the unrelated translocated promoter region (TPR) protein that activates the TPR-MET fusion kinase by mediating dimerization through its leucine zipper motif. This engineered TPR-ALK hybrid protein, which transformed cells almost as efficiently as NPM-ALK, was localized solely within the cytoplasm of cells. These data indicate that the nuclear and nucleolar localization of NPM-ALK, which probably occur because of transport via the shuttling activity of NPM, is not required for oncogenesis. Further, the activation of the truncated ALK protein by a completely heterologous oligomerization domain suggests that the functionally important role of the NPM segment of NPM-ALK in transformation is restricted to the formation of kinase-active oligomers and does not involve the alteration of normal NPM functions.

Indexed as

Anaplastic Lymphoma KinaseAnimalsCell LineCell NucleusCell Transformation, NeoplasticChromosomes, Human, Pair 2Chromosomes, Human, Pair 5Cloning, MolecularCytoplasmEnzyme ActivationHumansLymphoma, Non-HodgkinMutationNuclear ProteinsNucleophosminOncogene Proteins, FusionALK protein, humanAlk protein, ratAnaplastic Lymphoma KinaseNPM1 protein, humanNuclear ProteinsNucleophosminOncogene Proteins, FusionProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesRecombinant Fusion Proteins

Identifiers

PMID9121481
PMCPMC232080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.